BAKX Therapeutics
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
BAKX developed cancer therapies targeting the biological processes governing cell survival and death.
02 / BAKX Therapeutics FAILURE REASONS
Failure reasons
Founder Sree Kant said the board ended operations because of scientific challenges, the expected discovery timelines and difficult financing conditions. The explanation concerns the feasibility of continuing the research program under those conditions, not proof that a marketed drug harmed patients.
03 / EVENT HISTORY
Events in the structured record
- Research company started
The founder dates the start of BAKX to early 2020.
- Termination and staff departures
Most scientific staff were let go on 1 July; the founder announced that remaining employees, including himself, would leave by 1 August.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Scientific challenges and long discovery timelines
- 02
Difficult financing environment
- 03
Board decided to terminate operations
- 04
Scientific team and remaining staff let go